B



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Serial No.: 09/678,591

Docket No.: 2305-2-3

Steven C. Quay

Group Art Unit: 1614

Filing Date: October 3, 2000

Examiner: Dwayne C. Jones

Title: Long-Acting Oxytocin Analogues for the Treatment and Prevention of Breast

Cancer and Psychiatric Disorders

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this communication, and any document being attached hereto,

is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail addressed to: The Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450

is being transmitted via facsimile to _____

on this 20th day of May, 2004.

Signature

mouni

X Supplemental Information Disclosure Statement

X PTO-1449 w/references

X Postcard

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Steven C. Quay

Serial No.: 09/678,591

Group Art Unit: 1614

Filing Date: October 3, 2000

Examiner: Dwayne C. Jones

For: LONG-ACTING OXYTOCIN ANALOGUES FOR THE TREATMENT AND

PREVENTION OF BREAST CANCER AND PSYCHIATRIC DISORDERS

DATE OF DEPOSIT:

May 20, 2004

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER FOR PATENTS, P.O. Box 1450, ALEXANDRIA, NA 22313-1450

TYPED NAME: Donna Zimmerman

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the references listed on the attached Form PTO-1449 be **reconsidered** by the Examiner and made of record as of the original filing date of March 26, 2001.

Applicant is complying with the January 29, 2004 request of the Examiner to provide a supplemental list, so that all the references originally cited in the March 26, 2001 Information Disclosure Statement may be properly indicated as being considered. Applicant is providing a "clean" PTO-1449 form along with a copy of all the references that were originally lined out by the Examiner as not being considered because of the omission from the file of hard copies of the references.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information disclosed is, or is considered to be, prior art with respect to the present application or material to patentability as defined in 37 C.F.R. §§ 1.56.

Applicant believes that all the references listed on the original Information Disclosure Statement and PTO 1499 were sent to the United States Patent and Trademark Office on March 26, 2001, and therefore does not believe any fees are required in the submission of this Supplemental Information Disclosure Statement. However, should the Office determine that late submission fees are required for the filing of this Supplemental Information Disclosure Statement, Applicant requests that a telephone conference be conducted to expedite resolution by calling the undersigned at (425) 455-5575.

Respectfully submitted,

Dated: May 20, 2004

Jeffrey J. King

Registration No. 38,515

Graybeal Jackson Haley LLP

155 - 108th Avenue N.E., Suite 350

Bellevue, WA 98004-5901

(425) 455-5575

MAN 2 4 2004 PFORM

Form PTO-1449 Docket Number (Optional) Application Number 2305-2-3 09/678,591 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) Applicant(s) Dr. Steven C. Quay Group Art Unit Filing Date 1616 October 3, 2000 U.S. PATENT DOCUMENTS **EXAMINER DOCUMENT** DATE NAME **CLASS SUBCLASS** FILING DATE IF APPROPRIATE INITIAL NUMBER FOREIGN PATENT DOCUMENTS **DOCUMENT** DATE COUNTRY CLASS **SUBCLASS** Translation EXAMINER **INITIALS*** NUMBER YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Atke et al., "Uterotonic Activity and Myometrial Receptor Affinity of 1-Deamino-1-Carwba-2-Tyrosine (O-Methyl)-Oxytocin," Acta Endocrinol. 115:155-160, 1987 CB Boucher et al., "Double-Blind, Randomized Comparison of the Effect of Carbetocin and Oxytocin on Intraoperative Blood Loss and Uterine Tone of Patients Undergoing Cesarean Section," J. Perinatology 18:202-207, 1998 CC Bussolati et al., "Immunolocalization and Gene Expression of Oxytocin Receptors in Carcinomas and Non-Neoploastic Tissues of the Breast," Am. J. Pathol. 148:1895-1903, 1996 CD Cobo, E., "Characteristics of the Spontaneous Milk Ejecting Activity Occurring During Human Lactation," J. Perinat, Med. 21:77-85, 1993 CE Cort et al., "Effect of Oxytocin and its Long-Acting Analog on Milk Let-down and Intramammary Pressure in Healthy Lactating Sows," Am. J. Vet. Res. 43:1283-1285, 1982 CF Dansereau et al., "Double-Blind Comparison of Carbetocin Versus Oxytocin in Prevention of Uterine Atony After Cesarean Section," AM. J. Obstet. Gynecol. 180:670-676, 1999 CG Engstrom et al., "Oxzytocin Receptor Binding and Uterotonic Activity of Carbetocin and its Metabolites Following Enzymatic Degradation," Eur. J. Pharmacol. 355:203-210, 1998 СН Fay et al., "Oxytocin Does Not Induce A Rise in Intracellular Free Calcium in Human Breast Cancer Cells," Res. Commun. Mol. Pathol. Pharmacol. 103:115-128, 1999 CI Gonser, M., "Labor Induction and Augmentation with Oxytocin: Pharmacokinetic Considerations," Arch. Gynecol. Obstet. 256: 63-66, 1995 CJ Hunter et al.m "Effect of Carbetocin, A Long-Acting Oxytocin Analog on the Postpartum Uterus," Clin. Pharmacol. Ther. 52:60-67, 1992 **EXAMINER** DATE CONSIDERED EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the

• •

applicant.

Sheet 2 of 3 m PTO-1449 Docket Number (Optional) Application Number 09/678,591 2305-2-3 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) Applicant(s) Dr. Steven C. Quay Group Art Unit Filing Date 1616 October 3, 2000 **U.S. PATENT DOCUMENTS CLASS SUBCLASS** FILING DATE **EXAMINER** DOCUMENT DATE NAME INITIAL NUMBER IF APPROPRIATE FOREIGN PATENT DOCUMENTS **EXAMINER** DOCUMENT DATE COUNTRY CLASS **SUBCLASS** Translation INITIALS* NUMBER YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) DA Ito et al., "Investigation of the Oxytocin Recptor Expression in Human Breast Cancer Tissue Using Newly Established Monoclonal Antibodies," Endocrinology 137:773-779, 1996 DB Kimura et al., "Expression and Immunolocalization of the Oxytocin Receptor in Human Lactating and Non-Lactating Mammary Glands," Human Reprod. 13:2645-2653, 1998 DC Mena, F., "Central Effects of Catecholamines Upon Mammary Contractility in Rats Are Neurally Mediated," Neuroendocrinology 61: 722-730, 1995 DD Murrell, T.G.C. "The Potential for Oxytocin (OT) to Prevent Breast Cancer: A Hypothesis," Breast Cancer Res. Treat. 35:225-229, 1995 DE Murrell, "Epidemiological and Biochemical Support for a Theory on the Causes and Prevention of Breast Cancer," Med. Hypotheses 36:389-396, 1991 DF Nass et al., "The Biology of Breast Cancer," Hematol, Oncol. Clin. North Am., 13:311-332, 1999 DG Newton, N., "The Quantitative Effect of Oxytocin (Pitocin) on Human Milk Yield," Ann. N.Y. Acad. Sci. 652:481-483 DH Norström et al.,k "Contractile Effect of Oxytocin and 1-Deamino-1-Carba-2-Tyrosine (0-Methyl)-Oxytocin in Myometrial Tissue from Non-Pregnant and Term Pregnant Women," Acta Endocrinol. 122:566-568, 1990 DI Orhue, A., "Incremental Increases in Oxytocin Infusion Regimens for Induction of Labor at Term in Primigravidas: A Randomized Controlled Trial," Obstet. Gynecol. 83:229-233, 1994 DJ Planchon et al., "Alteration of Prostaglandin E Receptors in Advanced Breast Tumour Cell Lines," Mol. Cell. Endocrinol. 111:219-233, 1995 DK Sapino et al., "Oxytocin Receptor Within the Breast: Biological Function and Distribution," Anticancer Res. 18:2181-2186, 1998 **EXAMINER** DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

MAN 2 4 2004 Form PTO-1449
INFORMATION II
APPLICATION
(Use

<u> </u>					_				Sheet 3 of 3
Form PTO-14		Docket Number 2305-2-3	er (O	ptional)		Application Number 09/678,591			
APPLICATIO	CLOSURE CITATION								
(eral sheets if necessa	Applicant(s)	Applicant(s) Dr. Steven C. Quay						
		Filing Date Octo	Filing Date October 3, 2000			Group Art Unit 1616			
	PATENT DOCUM	ATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
			<u> </u>					<u> </u>	
			FOREIG	ON PATENT DOCU	IMEN	≀TS			***
EXAMINER INITIALS*		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	Translation	
	<u> </u>				<u> </u>			YES	NO
,		OTHER DOC	UMENTS (Inclu	uding Author, Title,	Date	, Pertinent	Pages, Etc.)		
	EA Sapino et al., "Oxytocin Enhance Myoepithelial Cell Differentiation and Proliferation in the Mouse Mammary Gland," Endocrinology 133:838-842 , 1993								
	ЕВ	Satin et al., "Factors Affecting the Dose Response to Oxytocin for Labor Stimulation," Am. J. Obstetl. Gynecol. 166:1260-1261, 1992 Satin et al., "High-Dose Oxytocin" 20-Versus 40-Minute Dosage Interval," Obstet. Gynecol. 83: 234-238, 1994 Silcox, et al., "Transfer of Carbetocin into Human Breast Milk," Obstet. Gynecol. 82:456-459, 1993							
	EC								
	ED								
	EE Taylor et al., "Interaction of Vasopressin and Oxytocin with Human Breast Carcinoma Cells," Cancer Res. 50:7882-7886, 1990								er Res.
	EF Van Dongen et al., "Ascending Dose Tolerance Study of Intramuscular Carbetocin Administered After N Vaginal Birth," <u>Eur. J. Obstet. Gynecol. Reprod. Biol.</u> 77:181-187, 1998								
	EG	Vilhardt et al., "Interaction of Chymotrypsin with Carbetocin ([1-Deamino-1-Monocarba-2-O-Methyltyrosine]-Oxytocin)," Pharmacol. Toxicol. 81:147-150, 1997							
	ļ								
	↓								
	 								
	 								<u> </u>
	 	<u> </u>			—				
EXAMINER	DATE (ONS	SIDERED						
		itation considered, whation if not in conforma						munication to	the